Home » Stocks » Calithera Biosciences

Calithera Biosciences, Inc. (CALA)

Stock Price: $4.24 USD -0.03 (-0.59%)
Updated Aug 14, 2020 9:59 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 298.82M
Revenue (ttm) n/a
Net Income (ttm) -86.86M
Shares Out 70.56M
EPS (ttm) -1.43
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 14, 2020
Last Price $4.24
Previous Close $4.26
Change ($) -0.03
Change (%) -0.59%
Day's Open 4.29
Day's Range 4.21 - 4.29
Day's Volume 27,962
52-Week Range 2.45 - 8.18

More Stats

Market Cap 298.82M
Enterprise Value 150.04M
Earnings Date (est) Nov 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 70.56M
Float 62.81M
EPS (basic) -1.43
EPS (diluted) -1.43
FCF / Share -1.20
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.80M
Short Ratio 6.21
Short % of Float 7.82%
Beta 2.10
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 2.02
Revenue n/a
Operating Income -89.40M
Net Income -86.86M
Free Cash Flow -83.10M
Net Cash 148.78M
Net Cash / Share 2.11
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -33.73%
ROE -61.46%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (6)

Buy 6
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(162.10% upside)
Current: $4.24
Target: 11.10
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth--14.26%------
Gross Profit-22.2525.96-----
Operating Income-92.90-57.28-29.69-38.33-32.82-21.72-12.38-7.98
Net Income-89.86-54.63-27.83-38.00-32.64-21.71-12.38-7.98
Shares Outstanding47.3136.6032.9519.4918.054.650.090.01
Earnings Per Share-1.90-1.49-0.84-1.95-1.81-4.67-131.53-366.13
Operating Cash Flow-78.75-64.8413.75-31.03-29.93-19.23-11.84-6.99
Capital Expenditures-0.01-0.21-1.23-0.40-0.44-0.56-0.16-0.05
Free Cash Flow-78.75-65.0612.52-31.43-30.37-19.79-12.00-7.04
Cash & Equivalents15813716451.8369.9710233.942.31
Total Debt6.72-------
Net Cash / Debt15113716451.8369.9710233.942.31
Book Value14212715049.9171.79100-20.81-8.57
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Calithera Biosciences, Inc.
Country United States
Employees 90
CEO Susan M. Molineaux

Stock Information

Ticker Symbol CALA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CALA
IPO Date October 2, 2014


Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors. The company also offers INCB001158, an oral inhibitor of arginase that is in Phase I/II clinical trial for the treatment of hematology and oncology. The company is also developing CB-280, an oral arginase inhibitor for the treatment of cystic fibrosis; and CB-708, an orally administered small molecule inhibitor of CD73. It has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. The company also has clinical trial collaboration with Bristol-Myers Squibb Company to evaluate nivolumab in combination with CB-839. In addition, it has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology. Calithera Biosciences, Inc. was founded in 2010 and is headquartered in South San Francisco, California.